MediciNova (MNOV) Stock Price, News & Analysis

Company Overview

MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory, and other serious medical conditions. The company is headquartered in La Jolla, California, and its programs are primarily directed toward conditions with significant unmet treatment needs.

Its lead investigational product, MN-166 (ibudilast), is being studied in several neurological indications, including amyotrophic lateral sclerosis, progressive multiple sclerosis, and substance use disorders. MediciNova is also developing MN-001 (tipelukast), an investigational therapy being evaluated for fibrotic and inflammatory diseases, including nonalcoholic steatohepatitis and pulmonary conditions. These products have not received broad regulatory approval for the indications under investigation.

MediciNova was founded in 2000 and has pursued a strategy of licensing and developing drug candidates for international markets, with research and clinical activities involving the United States and Japan. The company is led by Yuichi Iwaki, M.D., Ph.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $1.36 to $1.44
• 50-Day Range: $1.31 to $3.45
• 52-Week Range: $1.17 to $3.90
• Volume: 37,087 shs
• Average Volume: 392,384 shs
• Market Capitalization: $66.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.75
• Consensus Rating: Moderate Buy

MediciNova Stock Analysis - MarketRank™

MediciNova scored higher than 55% of companies evaluated by MarketBeat, and ranked 434th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MediciNova has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

MediciNova has a consensus price target of $7.75, representing about 469.9% upside from its current price of $1.36.

Amount of Analyst Coverage

MediciNova has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MediciNova are expected to decrease in the coming year, from ($0.25) to ($0.51) per share.

Price to Book Value per Share Ratio

MediciNova has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.80% of the float of MediciNova has been sold short.

Short Interest Ratio / Days to Cover

MediciNova has a short interest ratio ("days to cover") of 0.22, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MediciNova has recently decreased by 9.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MediciNova does not currently pay a dividend.

Dividend Growth

MediciNova does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

5 people have searched for MNOV on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added MediciNova to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MediciNova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,728,000.00 in company stock.

Percentage Held by Insiders

14.00% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

9.90% of the stock of MediciNova is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/20/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MNOV
• CIK: 1226616
• Web: medicinova.com
• Phone: (858) 373-1500
• Fax: 858-404-0048
• Employees: 6
• Year Founded: 2000

Price Target and Rating

• Average Price Target for MediciNova: $7.75
• High Price Target: $10.00
• Low Price Target: $6.00
• Potential Upside/Downside: +469.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12 million
• Net Margins: -1,168.70%
• Pretax Margin: -1,168.15%
• Return on Equity: -26.51%
• Return on Assets: -24.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.75
• Quick Ratio: 8.75

Sales & Book Value

• Annual Sales: $410 thousand
• Price / Sales: 163.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.85 per share
• Price / Book: 1.60

Miscellaneous

• Outstanding Shares: 49,220,000
• Free Float: 42,330,000
• Market Cap: $66.94 million
• Optionable: Optionable
• Beta: 0.61